| 1.08 0.01 (0.93%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.39  |
1-year : | 1.58 |
| Resists | First : | 1.19 |
Second : | 1.36 |
| Pivot price | 1.11 |
|||
| Supports | First : | 0.91 | Second : | 0.76 |
| MAs | MA(5) : | 1.03 |
MA(20) : | 1.12 |
| MA(100) : | 1.11 |
MA(250) : | 0.86 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 34.4 |
D(3) : | 28.8 |
| RSI | RSI(14): 43.4 |
|||
| 52-week | High : | 1.5 | Low : | 0.33 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ONCY ] has closed above bottom band by 38.9%. Bollinger Bands are 14% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.09 - 1.1 | 1.1 - 1.1 |
| Low: | 1.02 - 1.03 | 1.03 - 1.03 |
| Close: | 1.07 - 1.08 | 1.08 - 1.09 |
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Fri, 07 Nov 2025
Oncolytics Biotech Inc expected to post a loss of 10 cents a share - Earnings Preview - TradingView
Fri, 07 Nov 2025
Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Wed, 05 Nov 2025
Oncolytics Biotech (ONCY) to Release Earnings on Tuesday - MarketBeat
Tue, 28 Oct 2025
Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care - PR Newswire
Mon, 29 Sep 2025
Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 105 (M) |
| Shares Float | 99 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 3,210 (K) |
| Shares Short P.Month | 2,620 (K) |
| EPS | -0.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.05 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -74.6 % |
| Return on Equity (ttm) | -249.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -4.16 |
| PEG Ratio | 0 |
| Price to Book value | 18 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|